NO309704B1 - Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) - Google Patents

Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) Download PDF

Info

Publication number: NO309704B1
Authority: NO; Norway
Prior art keywords: fatty acids; dic; emulsion; treatment; dose
Prior art date: 1992-02-24

Application number

NO943102A

Other languages

English (en)

Norwegian (no)

Other versions

NO943102D0 (no

NO943102L (no

Inventor

Nils Egberg

Carin Larsson-Backstroem

Jan Jakobsson

Rolf Lundh

Original Assignee

Fresenius Kabi Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-24

Filing date

1994-08-23

Publication date

2001-03-19

1994-08-23 Application filed by Fresenius Kabi Ab filed Critical Fresenius Kabi Ab

1994-08-23 Publication of NO943102D0 publication Critical patent/NO943102D0/no

1994-10-21 Publication of NO943102L publication Critical patent/NO943102L/no

2001-03-19 Publication of NO309704B1 publication Critical patent/NO309704B1/no

Links

208000009190 disseminated intravascular coagulation Diseases 0.000 title claims abstract description 75
238000011282 treatment Methods 0.000 title claims abstract description 25
239000000194 fatty acid Substances 0.000 title claims description 69
235000014113 dietary fatty acids Nutrition 0.000 title claims description 57
229930195729 fatty acid Natural products 0.000 title claims description 57
150000004665 fatty acids Chemical class 0.000 title claims description 57
238000011161 development Methods 0.000 title claims description 16
238000004519 manufacturing process Methods 0.000 title claims description 10
230000002265 prevention Effects 0.000 title claims description 4
229940126601 medicinal product Drugs 0.000 title 1
239000000839 emulsion Substances 0.000 claims abstract description 57
239000003921 oil Substances 0.000 claims abstract description 39
238000002360 preparation method Methods 0.000 claims abstract description 30
150000003904 phospholipids Chemical class 0.000 claims abstract description 16
230000004872 arterial blood pressure Effects 0.000 claims abstract description 13
210000001147 pulmonary artery Anatomy 0.000 claims abstract description 9
239000000443 aerosol Substances 0.000 claims abstract description 8
239000002775 capsule Substances 0.000 claims abstract description 4
235000019198 oils Nutrition 0.000 claims description 38
235000021476 total parenteral nutrition Nutrition 0.000 claims description 13
239000003963 antioxidant agent Substances 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
239000008158 vegetable oil Substances 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 7
230000003078 antioxidant effect Effects 0.000 claims description 5
239000003995 emulsifying agent Substances 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
238000011866 long-term treatment Methods 0.000 claims description 2
239000000654 additive Substances 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
208000024891 symptom Diseases 0.000 abstract description 14
235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 4
229940012843 omega-3 fatty acid Drugs 0.000 abstract description 4
230000001575 pathological effect Effects 0.000 abstract description 4
150000003839 salts Chemical class 0.000 abstract description 4
239000006014 omega-3 oil Substances 0.000 abstract description 3
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
235000013311 vegetables Nutrition 0.000 abstract 1
238000001802 infusion Methods 0.000 description 40
230000000694 effects Effects 0.000 description 35
208000011580 syndromic disease Diseases 0.000 description 31
102000001399 Kallikrein Human genes 0.000 description 30
108060005987 Kallikrein Proteins 0.000 description 30
230000002829 reductive effect Effects 0.000 description 26
230000037396 body weight Effects 0.000 description 24
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 21
229940028435 intralipid Drugs 0.000 description 21
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 21
230000009467 reduction Effects 0.000 description 20
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 19
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 19
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
229960000187 tissue plasminogen activator Drugs 0.000 description 18
239000007924 injection Substances 0.000 description 17
238000002347 injection Methods 0.000 description 17
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
108010073385 Fibrin Proteins 0.000 description 14
102000009123 Fibrin Human genes 0.000 description 14
241001465754 Metazoa Species 0.000 description 14
108090000113 Plasma Kallikrein Proteins 0.000 description 14
229950003499 fibrin Drugs 0.000 description 14
235000021323 fish oil Nutrition 0.000 description 14
230000023597 hemostasis Effects 0.000 description 13
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
108010000499 Thromboplastin Proteins 0.000 description 11
102000002262 Thromboplastin Human genes 0.000 description 11
208000007536 Thrombosis Diseases 0.000 description 11
230000004913 activation Effects 0.000 description 11
230000015271 coagulation Effects 0.000 description 11
238000005345 coagulation Methods 0.000 description 11
229960000984 tocofersolan Drugs 0.000 description 11
235000006708 antioxidants Nutrition 0.000 description 10
108010049003 Fibrinogen Proteins 0.000 description 9
102000008946 Fibrinogen Human genes 0.000 description 9
230000001154 acute effect Effects 0.000 description 9
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 9
229940087168 alpha tocopherol Drugs 0.000 description 9
235000020673 eicosapentaenoic acid Nutrition 0.000 description 9
229940012952 fibrinogen Drugs 0.000 description 9
230000020764 fibrinolysis Effects 0.000 description 9
208000014674 injury Diseases 0.000 description 9
238000000034 method Methods 0.000 description 9
239000002076 α-tocopherol Substances 0.000 description 9
235000004835 α-tocopherol Nutrition 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
241000282887 Suidae Species 0.000 description 8
235000021342 arachidonic acid Nutrition 0.000 description 8
229940114079 arachidonic acid Drugs 0.000 description 8
230000036772 blood pressure Effects 0.000 description 8
239000002158 endotoxin Substances 0.000 description 8
108010073651 fibrinmonomer Proteins 0.000 description 8
230000003480 fibrinolytic effect Effects 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
235000016709 nutrition Nutrition 0.000 description 8
230000008092 positive effect Effects 0.000 description 8
208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
230000008733 trauma Effects 0.000 description 8
102000003827 Plasma Kallikrein Human genes 0.000 description 7
230000009286 beneficial effect Effects 0.000 description 7
230000023555 blood coagulation Effects 0.000 description 7
235000020669 docosahexaenoic acid Nutrition 0.000 description 7
239000003527 fibrinolytic agent Substances 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
210000000952 spleen Anatomy 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
102000003820 Lipoxygenases Human genes 0.000 description 6
108090000128 Lipoxygenases Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000003110 anti-inflammatory effect Effects 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
150000002066 eicosanoids Chemical class 0.000 description 6
230000002439 hemostatic effect Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000002960 lipid emulsion Substances 0.000 description 6
229920006008 lipopolysaccharide Polymers 0.000 description 6
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
230000002685 pulmonary effect Effects 0.000 description 6
150000003595 thromboxanes Chemical class 0.000 description 6
229930003427 Vitamin E Natural products 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229960001123 epoprostenol Drugs 0.000 description 5
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
210000002216 heart Anatomy 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
230000003859 lipid peroxidation Effects 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000002504 physiological saline solution Substances 0.000 description 5
239000003549 soybean oil Substances 0.000 description 5
235000012424 soybean oil Nutrition 0.000 description 5
230000006641 stabilisation Effects 0.000 description 5
238000011105 stabilization Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 5
210000002700 urine Anatomy 0.000 description 5
229940046009 vitamin E Drugs 0.000 description 5
235000019165 vitamin E Nutrition 0.000 description 5
239000011709 vitamin E Substances 0.000 description 5
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 4
108010002352 Interleukin-1 Proteins 0.000 description 4
206010073734 Microembolism Diseases 0.000 description 4
208000034486 Multi-organ failure Diseases 0.000 description 4
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
229930003268 Vitamin C Natural products 0.000 description 4
102000003801 alpha-2-Antiplasmin Human genes 0.000 description 4
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 4
239000004019 antithrombin Substances 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000004087 circulation Effects 0.000 description 4
230000008021 deposition Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
230000002526 effect on cardiovascular system Effects 0.000 description 4
239000008344 egg yolk phospholipid Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
239000002502 liposome Substances 0.000 description 4
230000007774 longterm Effects 0.000 description 4
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
229940012957 plasmin Drugs 0.000 description 4
230000004044 response Effects 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
230000002485 urinary effect Effects 0.000 description 4
235000019154 vitamin C Nutrition 0.000 description 4
239000011718 vitamin C Substances 0.000 description 4
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
208000010392 Bone Fractures Diseases 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
206010017076 Fracture Diseases 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
208000010718 Multiple Organ Failure Diseases 0.000 description 3
102000013566 Plasminogen Human genes 0.000 description 3
108010051456 Plasminogen Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108090000190 Thrombin Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
230000002785 anti-thrombosis Effects 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000003114 blood coagulation factor Substances 0.000 description 3
238000004820 blood count Methods 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
-1 corticoid steroid Chemical class 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940068998 egg yolk phospholipid Drugs 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
239000007789 gas Substances 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
229940118019 malondialdehyde Drugs 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
230000036407 pain Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002040 relaxant effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
229960004072 thrombin Drugs 0.000 description 3
230000036325 urinary excretion Effects 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
239000011627 DL-alpha-tocopherol Substances 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
206010038687 Respiratory distress Diseases 0.000 description 2
206010047141 Vasodilatation Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
230000003024 amidolytic effect Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
235000018823 dietary intake Nutrition 0.000 description 2
229940090949 docosahexaenoic acid Drugs 0.000 description 2
229960005135 eicosapentaenoic acid Drugs 0.000 description 2
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000029142 excretion Effects 0.000 description 2
230000006624 extrinsic pathway Effects 0.000 description 2
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
230000008629 immune suppression Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
238000007726 management method Methods 0.000 description 2
201000011475 meningoencephalitis Diseases 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
229940037525 nasal preparations Drugs 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
230000003334 potential effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
150000003815 prostacyclins Chemical class 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
150000003591 thromboxane A2 derivatives Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
210000000626 ureter Anatomy 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
230000003519 ventilatory effect Effects 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
RJHNVFKNIJQTQF-LMIBIYGPSA-N 2,3-Dinor-TXB2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CC(O)=O RJHNVFKNIJQTQF-LMIBIYGPSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229940122601 Esterase inhibitor Drugs 0.000 description 1
108010080865 Factor XII Proteins 0.000 description 1
102000000429 Factor XII Human genes 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019345 Heat stroke Diseases 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
206010058558 Hypoperfusion Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
208000004078 Snake Bites Diseases 0.000 description 1
229930182558 Sterol Chemical class 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000003441 Transfusion reaction Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000489 anti-atherogenic effect Effects 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000010473 blackcurrant seed oil Substances 0.000 description 1
239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
235000021324 borage oil Nutrition 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000004154 complement system Effects 0.000 description 1
229940012193 contrave Drugs 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
238000007865 diluting Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
239000002329 esterase inhibitor Substances 0.000 description 1
125000004494 ethyl ester group Chemical class 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
238000004868 gas analysis Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000008821 health effect Effects 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229940039412 ketalar Drugs 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229960003379 pancuronium bromide Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000016236 parenteral nutrition Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000009101 premedication Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000003331 prothrombotic effect Effects 0.000 description 1
238000007348 radical reaction Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004243 retinal function Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
235000014102 seafood Nutrition 0.000 description 1
208000037974 severe injury Diseases 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
235000020238 sunflower seed Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001026 thromboplastic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
229960000401 tranexamic acid Drugs 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
210000001631 vena cava inferior Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Emergency Medicine (AREA)
Mycology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Hematology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Marine Sciences & Fisheries (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

NO943102A 1992-02-24 1994-08-23 Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) NO309704B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9200541A SE9200541D0 (sv)	1992-02-24	1992-02-24	New usee of omega-3-fatty acids
PCT/SE1993/000146 WO1993016691A1 (en)	1992-02-24	1993-02-23	New use of omega-3-fatty acids

Publications (3)

Publication Number	Publication Date
NO943102D0 NO943102D0 (no)	1994-08-23
NO943102L NO943102L (no)	1994-10-21
NO309704B1 true NO309704B1 (no)	2001-03-19

Family

ID=20385410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO943102A NO309704B1 (no)	1992-02-24	1994-08-23	Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC)

Country Status (13)

Country	Link
US (2)	US5747533A (da)
EP (1)	EP0627918B1 (da)
JP (1)	JP3559280B2 (da)
AT (1)	ATE207744T1 (da)
AU (1)	AU671438B2 (da)
CA (1)	CA2117535A1 (da)
DE (1)	DE69331051T2 (da)
DK (1)	DK0627918T3 (da)
ES (1)	ES2162620T3 (da)
NO (1)	NO309704B1 (da)
SE (1)	SE9200541D0 (da)
SG (1)	SG46238A1 (da)
WO (1)	WO1993016691A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0987176A (ja) *	1995-09-26	1997-03-31	Shiseido Co Ltd	糸球体腎炎抑制剤
EP1004303B1 (en) *	1997-06-16	2004-10-13	Nippon Suisan Kaisha, Ltd.	Composition having capability of removing risk factor during exercise
US6054481A (en)	1998-01-21	2000-04-25	Fideline	Pig appeasing pheromones for enhancing weight gain in a mammal
JP4754688B2 (ja) *	1998-01-21	2011-08-24	フィドゥラン	ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン
US6077867A (en) *	1998-01-21	2000-06-20	Fideline	Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
EP1220669A4 (en) *	1999-10-13	2004-12-08	Marco A Chacon	THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
FR2804023B1 (fr) *	2000-01-26	2002-09-20	Johnson & Johnson Consumer Fr	Complement nutritionnel a base d'huile de pepins de cassis
WO2002069964A1 (en) *	2001-03-05	2002-09-12	Ernest Stephen P	Enteral formulation
US8729124B2 (en) *	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
US7323206B1 (en)	2003-03-04	2008-01-29	B. Braun Medical Inc.	Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
US9801982B2 (en)	2004-09-28	2017-10-31	Atrium Medical Corporation	Implantable barrier device
WO2006036984A2 (en)	2004-09-28	2006-04-06	Atrium Medical Corporation	Stand-alone film and methods for making the same
US9012506B2 (en)	2004-09-28	2015-04-21	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US20060088596A1 (en)	2004-09-28	2006-04-27	Atrium Medical Corporation	Solubilizing a drug for use in a coating
US20060135610A1 (en) *	2004-12-22	2006-06-22	Bortz Jonathan D	Cardiovascular compositions
EP1896059B1 (en) *	2005-06-24	2012-12-19	Drugrecure ApS	Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
US9278161B2 (en)	2005-09-28	2016-03-08	Atrium Medical Corporation	Tissue-separating fatty acid adhesion barrier
US9427423B2 (en)	2009-03-10	2016-08-30	Atrium Medical Corporation	Fatty-acid based particles
CA2641852A1 (en) *	2006-02-10	2007-08-16	Sportscom Danmark Aps	Coated tablets, their methods of preparation, and related uses
WO2008057344A2 (en)	2006-11-06	2008-05-15	Atrium Medical Corporation	Coated surgical mesh
US9492596B2 (en)	2006-11-06	2016-11-15	Atrium Medical Corporation	Barrier layer with underlying medical device and one or more reinforcing support structures
US20080207756A1 (en) *	2007-02-27	2008-08-28	Atrium Medical Corporation	Bio-absorbable oil suspension
WO2009052182A1 (en)	2007-10-15	2009-04-23	Jbs United, Inc.	Method for increasing performance of offspring
WO2009009040A2 (en) *	2007-07-06	2009-01-15	Baum Seth J	Fatty acid compositions and methods of use
WO2009058799A1 (en) *	2007-11-01	2009-05-07	Wake Forest University School Of Medicine	Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) *	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100323028A1 (en) *	2007-11-30	2010-12-23	Jbs United, Inc.	Method and composition for treating pulmonary hemorrhage
US20110038910A1 (en)	2009-08-11	2011-02-17	Atrium Medical Corporation	Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) *	2009-08-24	2011-02-24	Atrium Medical Corporation	Nanoemulsion formulations for direct delivery
WO2011103514A1 (en) *	2010-02-18	2011-08-25	Martek Biosciences Corporation	Dha triglyceride emulsions
US20110200645A1 (en) *	2010-02-18	2011-08-18	Martek Biosciences Corporation	DHA Free Fatty Acid Emulsions
EP2593141B1 (en)	2010-07-16	2018-07-04	Atrium Medical Corporation	Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20210176999A1 (en)	2011-04-17	2021-06-17	Omega Foods, LLC	Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US9867880B2 (en)	2012-06-13	2018-01-16	Atrium Medical Corporation	Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9233114B2 (en)	2013-12-05	2016-01-12	Buriva, LLC	Dietary supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en)	2013-12-05	2017-01-24	Burvia, LLC.	Composition containing phospholipid-DHA and folate
US9216199B2 (en)	2013-12-05	2015-12-22	Buriva, LLC	Nutritional supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en)	2013-12-05	2017-04-04	Buriva, LLC.	Composition containing phospholipid-DHA and B vitamins
US10183044B2 (en) *	2015-05-15	2019-01-22	P Tech, Llc	Systems and methods for thrombosis prevention
US9655847B1 (en) *	2016-07-18	2017-05-23	National Guard Health Affairs	Therapeutic liposome and method of treating a subject having cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4752618A (en) *	1984-07-12	1988-06-21	New England Deaconess Hospital	Method of minimizing efects of infection through diet
US4678808A (en) *	1985-10-15	1987-07-07	Baxter Travenol Laboratories, Inc.	Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3785667T2 (de) *	1986-09-17	1994-07-21	Clintec Nutrition Co	Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen.
DE3719097C1 (de) *	1987-06-06	1988-06-09	Fratzer Uwe	Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8729751D0 (en) *	1987-12-21	1988-02-03	Norsk Hydro As	Feed additive & feed containing such additive
GB8819110D0 (en) *	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
US5223285A (en) *	1992-03-31	1993-06-29	Abbott Laboratories	Nutritional product for pulmonary patients

1992
- 1992-02-24 SE SE9200541A patent/SE9200541D0/xx unknown
1993
- 1993-02-23 WO PCT/SE1993/000146 patent/WO1993016691A1/en active IP Right Grant
- 1993-02-23 SG SG1996001422A patent/SG46238A1/en unknown
- 1993-02-23 JP JP51475493A patent/JP3559280B2/ja not_active Expired - Lifetime
- 1993-02-23 AU AU36529/93A patent/AU671438B2/en not_active Ceased
- 1993-02-23 DK DK93905710T patent/DK0627918T3/da active
- 1993-02-23 EP EP93905710A patent/EP0627918B1/en not_active Expired - Lifetime
- 1993-02-23 AT AT93905710T patent/ATE207744T1/de active
- 1993-02-23 DE DE69331051T patent/DE69331051T2/de not_active Expired - Lifetime
- 1993-02-23 CA CA002117535A patent/CA2117535A1/en not_active Abandoned
- 1993-02-23 ES ES93905710T patent/ES2162620T3/es not_active Expired - Lifetime
- 1993-02-23 US US08/290,905 patent/US5747533A/en not_active Expired - Lifetime
1994
- 1994-08-23 NO NO943102A patent/NO309704B1/no not_active IP Right Cessation
1995
- 1995-06-07 US US08/483,977 patent/US5731346A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5747533A (en)	1998-05-05
NO943102D0 (no)	1994-08-23
AU671438B2 (en)	1996-08-29
ATE207744T1 (de)	2001-11-15
SG46238A1 (en)	1998-02-20
ES2162620T3 (es)	2002-01-01
DE69331051D1 (de)	2001-12-06
NO943102L (no)	1994-10-21
DE69331051T2 (de)	2002-06-13
EP0627918B1 (en)	2001-10-31
WO1993016691A1 (en)	1993-09-02
JP3559280B2 (ja)	2004-08-25
AU3652993A (en)	1993-09-13
EP0627918A1 (en)	1994-12-14
JPH07507766A (ja)	1995-08-31
CA2117535A1 (en)	1993-09-02
US5731346A (en)	1998-03-24
SE9200541D0 (sv)	1992-02-24
DK0627918T3 (da)	2002-01-14

Publication	Publication Date	Title
NO309704B1 (no)	2001-03-19	Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC)
Anez‐Bustillos et al.	2016	Intravenous fat emulsion formulations for the adult and pediatric patient: understanding the differences
Vanschoonbeek et al.	2003	Fish oil consumption and reduction of arterial disease
Jain et al.	2015	Omega-3 fatty acids and cardiovascular disease
DeCaterina et al.	1990	Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery.
Waitzberg et al.	2006	New parenteral lipid emulsions for clinical use
Mehta et al.	1988	Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease: effects on indices of platelet and neutrophil function and exercise performance
McCann et al.	1980	Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts
KR100793048B1 (ko)	2008-01-10	장쇄 다가불포화 지방산을 함유하는 유아식
Ott et al.	2011	Lipids in critical care medicine
US20020055539A1 (en)	2002-05-09	Compositions and methods for treating cardiovascular conditions
Carrel et al.	1998	Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only
Neumayer et al.	2006	Combined enzymatic and antioxidative treatment reduces ischemia-reperfusion injury in rabbit skeletal muscle
McClaskey et al.	2007	Subdural hematoma after a fall in an elderly patient taking high‐dose omega‐3 fatty acids with warfarin and aspirin: case report and review of the literature
EP1272169B1 (en)	2008-11-19	Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
Kılıcoglu et al.	2008	The ultrastructural research of liver in experimental obstructive jaundice and effect of honey
Knapp	1995	Omega-3 fatty acids in respiratory diseases: a review.
Lin	2021	Stroke and diets–A review
Svaneborg et al.	2002	The acute and short-time effect of supplementation with the combination of n− 3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids
Bernabe-Garcia et al.	2011	Beneficial effects of the n-3 long-chain polyunsaturated fatty acids in surgical patients: updating the evidence
Koch et al.	2005	Benefits of ω-3 fatty acids in parenteral nutrition
YLI-MĀYRY et al.	1992	Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion
Hamazaki et al.	2014	The safety of fish oils for those whose risk of injury is high
Calder	2003	Lipids and the critically ill patient
Chu et al.	1997	Daily supplementation with MaxEPA suppresses endotoxin-inducible monocytic procoagulation in dogs

Legal Events

Date	Code	Title	Description
2013-03-11	MK1K	Patent expired